Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026)
Tg Therapeutics (TGTX) recorded quarterly Current Deferred Revenue of $17.2 million in Q1 2026, down 19.04% quarter-over-quarter from $21.2 million in Q4 2025, and up 0.65% on a YoY basis from $17.1 million in Q1 2025.
Tg Therapeutics (TGTX) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Tg Therapeutics' Current Deferred Revenue history runs 15 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 0.65% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (up 0.65% YoY), while the FY2025 annual figure was $21.2 million, up 86.03% from the prior year.
- Current Deferred Revenue was $17.2 million for Q1 2026 at Tg Therapeutics, down from $21.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $26.4 million in Q3 2025 to a low of $152000.0 in Q4 2023.
- Historically, Current Deferred Revenue has averaged $8.4 million across 5 years, with a median of $3.4 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 69.6% in 2023, then soared 7409.21% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $500000.0 in 2022, then plunged by 69.6% to $152000.0 in 2023, then jumped by 7409.21% to $11.4 million in 2024, then surged by 86.03% to $21.2 million in 2025, then retreated by 19.04% to $17.2 million in 2026.
- The last three Current Deferred Revenue figures came in at $17.2 million (Q1 2026), $21.2 million (Q4 2025), and $26.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.19 Mn |
| Dec 31, 2025 | 21.23 Mn |
| Sep 30, 2025 | 26.40 Mn |
| Jun 30, 2025 | 23.91 Mn |
| Mar 31, 2025 | 17.08 Mn |
| Dec 31, 2024 | 11.41 Mn |
| Sep 30, 2024 | 9.09 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.37 Mn |
| Dec 31, 2023 | 152,000.00 |
| Sep 30, 2023 | 6.90 Mn |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 400,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Mar 31, 2022 | 600,000.00 |
| Dec 31, 2021 | 600,000.00 |
| Sep 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 700,000.00 |